Atreca (FRA:0C1) Construction In Progress : €0.00 Mil (As of Sep. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Atreca Construction In Progress?

Atreca's quarterly construction in progress increased from Mar. 2023 (€0.19 Mil) to Jun. 2023 (€0.25 Mil) but then declined from Jun. 2023 (€0.25 Mil) to Sep. 2023 (€0.00 Mil).

Atreca's annual construction in progress declined from Dec. 2020 (€11.82 Mil) to Dec. 2021 (€0.00 Mil) but then increased from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€0.17 Mil).

Atreca Construction In Progress Historical Data

The historical data trend for Atreca's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atreca Construction In Progress Chart

Atreca Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Construction In Progress

Get a 7-Day Free Trial

0.12

11.82

0.17

Atreca Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Construction In Progress	Get a 7-Day Free Trial															-	0.17	0.19	0.25	-

Atreca Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Atreca (FRA:0C1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atreca Inc (FRA:0C1) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

BCEL:USA 0C1:Germany

Address

835 Industrial Road, Suite 400, San Carlos, CA, USA, 94070

Website

https://www.atreca.com

Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. It has single segment business of therapeutic drug discovery and development. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.

Atreca (FRA:0C1) Headlines

No Headlines